ESH MM 2018 | MRD sequencing test approved for MM in the US
Nikhil Munshi
• 5 Oct 2018
Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the prospects for measurable residual disease (MRD) testing following the recent FDA approval of a deep sequencing-based technique for MRD detection in multiple myeloma (MM). This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
